A powerful and inexpensive technique for rewriting snippets of DNA — known as CRISPR-Cas9 — has two research institutions locked in a bitter patent battle.
A powerful and inexpensive technique for rewriting snippets of DNA — known as CRISPR-Cas9 — has two research institutions locked in a bitter patent battle.